CUPERTINO, Calif., July 25, 2019 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX) today announced that it will report
second quarter and six months ended June 30,
2019 financial results and host a conference call after the
market close on Thursday, August 1,
2019.
Thursday, August 1 at
4:30 p.m. Eastern Time/1:30 p.m. Pacific Time
Toll
Free:
877-407-0784
International:
201-689-8560
Conference
ID:
13692344
Webcast:
http://public.viavid.com/index.php?id=135202
A live audio webcast of the presentation will be also available
by accessing DURECT's homepage at www.durect.com and clicking
"Investors." If you are unable to participate during the live
webcast, the call will be archived on DURECT's website under Event
Calendar in the "Investors" section.
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR‑928, a new chemical
entity in Phase 2 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally
bioavailable small molecule, DUR-928 has been shown in preclinical
studies to play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may
include acute organ injury such as alcoholic Hepatitis (AH) and
acute kidney injury (AKI), chronic hepatic diseases such as
nonalcoholic steatohepatitis (NASH), and inflammatory skin
conditions such as psoriasis and atopic dermatitis. DURECT's
advanced oral and injectable delivery technologies are designed to
enable new indications and enhanced attributes for small-molecule
and biologic drugs. Key product candidates in this category
include POSIMIR® (bupivacaine extended-release
solution), an investigational locally-acting, non-opioid analgesic
intended to provide up to 3 days of continuous pain relief after
surgery, a long-acting injectable SABER-based HIV investigational
product being developed with Gilead and ORADUR™-Methylphenidate ER
Capsules, approved in Taiwan as
Methydur Sustained Release Capsules, where it is indicated for the
treatment of attention deficit hyperactivity disorder (ADHD).
In addition, for the assignment of certain patent
rights, DURECT receives single digit sales-based earn-out payments
from U.S. net sales of Indivior's PERSERIS™
(risperidone) drug for schizophrenia, which was commercially
launched in February 2019. In July
2019 we executed an exclusive license agreement with Gilead
for a long-acting injectable HIV investigational product utilizing
DURECT's SABER® technology, entailing an upfront of
$25 million, up to $145 in additional milestone payments plus tiered
royalties and an exclusive option to license additional SABER-based
products directed to HIV and HBV for an additional
$150 million per product in upfront
and milestones plus royalties. For more information about
DURECT, please visit www.durect.com.
NOTE: POSIMIR®, SABER® and
ORADUR™ are trademarks of DURECT Corporation. Other
referenced trademarks belong to their respective owners. DUR-928
and POSIMIR are drug candidates under development and have not been
approved for commercialization by the U.S. Food and Drug
Administration or other health authorities.
DURECT Forward-Looking Statement
The statements in
this press release regarding the potential benefits and uses of
DURECT's drug candidates, including the potential use of DUR-928 to
treat Alcoholic Hepatitis, hepatic and renal diseases such as NASH,
and inflammatory skin conditions such as psoriasis and atopic
dermatitis, the potential use of POSIMIR to treat post-surgical
pain, the potential of the long-acting injectable SABER-based HIV
investigational product being developed with Gilead to treat HIV,
the potential use of ORADUR-Methylphenidate to treat ADHD, the
potential for sales-based earn-out payments from the sale of
Indivior's PERSERIS to treat schizophrenia, and the potential
development of a long-acting injectable SABER-based HIV product
with Gilead and associated potential payments to DURECT are
forward-looking statements involving risks and uncertainties that
can cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
include, but are not limited to, the possibility that studies of
DUR-928 will not replicate results from earlier preclinical or
clinical trials, the risks that PERSERIS will not obtain market
acceptance and meaningful sales, as well as possible adverse events
associated with the use of PERSERIS, POSIMIR,
ORADUR-Methylphenidate, the long-acting injectable SABER-based HIV
investigational product being developed with Gilead and DUR-928,
and delays and costs due to additional work or other requirements
imposed by regulatory agencies for continued development, approval
or sale of POSIMIR, the long-acting injectable SABER-based HIV
investigational product being developed with Gilead,
ORADUR-Methylphenidate and DUR-928. Further information
regarding risks related to DUR-928, POSIMIR and
ORADUR-Methylphenidate and other risks related to DURECT is
included in DURECT's Form 10-Q filed on May
8, 2019 under the heading "Risk Factors."
View original
content:http://www.prnewswire.com/news-releases/durect-corporation-to-announce-second-quarter-2019-financial-results-on-august-1-300891306.html
SOURCE DURECT Corporation